PolyProx Therapeutics Raises an Additional £1 Million Seed Financing From New Investor, LifeArc, to Validate Polyproxin® Drug Leads in Oncology

PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.